Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000154
Chunk: 1

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 1
---
,057,182 |
| Net cash used in investing activities                                     |     |                                            |                             -231,824 |     |      |                              -81,326 |     |      |                     -367,060 |
| Net cash from (used in) financing activities                              |     |                                            |                              206,336 |     |      |                             -226,881 |     |      |                     -751,425 |
| Cash and cash equivalents at the end of the period                        |     |                                            |                              859,015 |     |      |                              681,486 |     |      |                      385,113 |

*1 All amounts shown are rounded to the nearest million JPY.

*2 The key consolidated financial data for the year ended March 31, 2025 is based on the consolidated financial statements prepared in accordance with International Financial Reporting Standards (IFRS). The key consolidated financial data for the six-month period ended September 30, 2024 and 2025 are based on the condensed interim consolidated financial statements prepared in accordance with IAS 34.

### 2. Business Overview
There has been no significant change in our business for the six-month period ended September 30, 2025.

As of September 30, 2025, Takeda consisted of 169 entities comprised of 156 consolidated subsidiaries (including partnerships), 12 associates ＊ accounted for using the equity method, and Takeda Pharmaceutical Company Limited. There has been no significant change in our group companies for the six-month period ended September 30, 2025.

* Associates include a joint venture.

<div align='center'>- 2 -</div>

Translation for reference purpose only

### II. Operating and Financial Review

#### 1. Risk Factors
There were no new risk factors identified for the six-month period ended September 30, 2025 as well as no significant changes in the risk factors compared to what we reported in our Annual Securities Report for the year ended March 31, 2025 which was filed in Japan.

2. Analysis on Business Performance, Financial Position and Cash Flows

( 1) Consolidated Financial Results (April 1 to September 30, 2025)

|                                                                                  |     |            |     |         |     |           |     |         |     |          |     |        |     |       |   |     |     |       | Billion JPY or percentage |
|                                                                                  |     | FY2024 H1  |